NCT01454934 2023-06-22A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung CancerEisai Inc.Phase 3 Completed540 enrolled 11 charts